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Objective: A pro-inflammatory imbalance in the tumor necrosis factor (TNF) system may 
contribute to the pathogenesis of schizophrenia (SCZ) and bipolar disorders (BD) and related 
comorbidities. We investigated the relative distribution of TNF related molecules in blood and 
dorsolateral prefrontal cortex (DLPFC) in these disorders.  
Method: We measured plasma levels of TNF, soluble TNF receptor 1 (sTNFR1), soluble TNF 
receptor 2 (sTNFR2) and A Disintegrin And Metalloprotease-17 (ADAM17) using enzyme 
immunoassays, and calculated the TNF/sTNFRs ratio (TNF/sTNFR1+sTNFR2) in a sample of 816 
SCZ and BD spectrum patients and 624 healthy controls (HC). TNF, TNFRSF1A (TNFR1), 
TNFRSF1B (TNFR2) and ADAM17 mRNA levels were determined in whole blood, and post-
mortem DLPFC obtained from an independent cohort (n=80 SCZ, n=44 BD, and n=86 HC). 
Results: In peripheral blood, we show increased TNF-related measures in patients compared to HC, 
with an increased TNF/sTNFRs ratio (p = 6.00x10
-5
), but decreased TNF mRNA expression 
(p=1x10
-4
), with no differences between SCZ and BD. Whole blood ADAM17 mRNA expression 
was markedly higher in BD vs. SCZ patients (p=1.40x10
-14
) and vs. HC (p=1.22x10
-8
). In post-
mortem DLPFC, we found no significant differences in mRNA expression of TNF pathway genes 
between any groups. 
Conclusions: SCZ and BD patients have increased plasma TNF pathway markers without 
corresponding increase in blood cell gene expression. ADAM17 expression in leukocytes is 
markedly different between the two disorders, while alterations in TNF related gene expression in 
DLPFC is uncertain. Further studies are necessary to elucidate the aberrant regulation of the TNF 
pathway in severe mental disorders. 
 




A dysregulation of the immune system due to chronically activated macrophages and T-cells has 
been proposed to contribute to the pathogenesis of schizophrenia (SCZ)
1
 and bipolar disorder (BD)
2
. 
Several lines of evidence support a pro-inflammatory profile in both diseases, where alterations in 
the tumor necrosis factor (TNF)-pathway, consisting of soluble and membrane bound TNF 
(formerly TNF-alpha) and its two receptors, have been reported in peripheral blood
2,3
. However, the 
regulation and the site of production of TNF related molecules in these disorders are far from clear. 
TNF is a pro-inflammatory cytokine expressed by macrophages, other leukocyte subsets and 
endothelial cells
4-6
, as well as by neurons, astrocytes and microglia that have a macrophage 
phenotype. It signals through two distinct membrane-bound receptors: TNF receptor 1 (TNFR1) 
and TNF receptor 2 (TNFR2) of which TNFR1 is widely distributed in a range of cells and tissues 
whereas TNFR2 is more selectively expressed by immune cells, endothelial cells, specific neuronal 
subtypes and glia cells
7
. Under physiological conditions TNF has been known to regulate synaptic 
transmission, neurotransmission, homeostatic synaptic scaling, neurogenesis and long term 
potentiation
8-10
. TNF and its receptors are produced as transmembrane proteins with an extracellular 
domain that can be proteolytically cleaved from the cell surface by metalloproteases like A 
Disintegrin And Metalloprotease-17 (ADAM17) resulting in soluble TNF, soluble (s)TNFR1 and 





, but to this end, no large studies have evaluated if this leads to a pro-
inflammatory imbalance between TNF and its soluble receptors, i.e., the TNF/sTNFRs ratio that 
reflects activity in the TNF system and correlates with TNF bioactivity
12
.  
Previously, modestly sized studies have demonstrated increased TNF mRNA expression in 
monocytes and lymphocytes in SCZ and BD
13-15
. To our knowledge, however, TNF, TNF receptor 
superfamily [TNFRSF] 1A and TNFRSF1B (denoted by TNFR1 and TNFR2, respectively, in the 
5 
 
present manuscript), and ADAM17 mRNA expression in whole blood cells have not been 
investigated in a well-powered sample of patients with severe mental disorders.  
The dorsolateral prefrontal cortex (DLPFC) is associated with a range of complex behaviors 
frequently referred to as executive functions, including working memory
16
, cognitive and 
behavioral flexibility, and abstract reasoning, all of which have been implicated in SCZ and to a 
lesser extent in BD
17-19
. We have previously found that general cognitive abilities were negatively 
associated with plasma TNFR1 levels in adults with SCZ and BD
20
. Moreover, a post-mortem study 
found elevated levels of TNFR1 mRNA in the frontal cortex in SCZ and increased transmembrane 
TNF in BD suggesting alterations in the TNF-pathway in the central nervous system in both 
illnesses
21
. However, large postmortem studies of TNF-pathway gene expression in the DLPFC are 
lacking.   
The aim of the present study was to further determine the role of TNF-pathway related molecules at 
the protein and mRNA levels in BD and SCZ patients. First we investigated these markers, 
including the balance between TNF and its receptors, in peripheral blood in a large cohort (n=1440). 
We then investigated whether TNF proteins and their proportion is associated with working 
memory, a task affiliated with the DLPFC. Lastly, mRNA levels of these molecules were examined 
in the DLPFC in an independent cohort (n=210). We hypothesized that patients with SCZ and BD 
would present with a distinct systemic and cortical pattern of TNF-pathway markers reflecting the 
relative contribution of these different compartments to the sustained systemic TNF activation that 




Plasma and leukocyte cohort 
Study Design and Ethics: The TOP Study at the NORMENT Centre, Oslo University Hospital, and 
collaborating Norwegian hospitals
22
 was approved by the Regional Committee for Medical 
Research Ethics and the Norwegian Data Inspectorate. The biobank was approved by the 
Norwegian Directorate of Health. All participants provided written informed consent after receiving 
a description of the study. 
Participants: The main inclusion criteria were DSM-IV diagnoses of schizophrenia spectrum 
disorders or bipolar spectrum disorders, IQ > 70 and age between 18 and 65 years (for details see
22
). 
Healthy volunteers without any history of severe psychiatric disorders (or in any of their first-
degree relatives), or substance/alcohol abuse/dependency from the same catchment area were 
randomly selected from the National Population Registry (www.ssb.no). (For details see
22
)  For the 
present analyses, patients and controls were not included if they had coexisting autoimmune or 
inflammatory disease, cancer, ongoing infections, used anti-inflammatory drugs or had C-reactive 
Protein (CRP) levels above 20 mg/L. 
 
Clinical Assessments: Diagnosis was obtained using the Structured Clinical Interview for DSM-IV 
Axis I Disorders (SCID-I). Clinical symptoms were evaluated using the Young Mania Rating Scale 
(YMRS), Inventory of Depressive Symptoms (IDS), Calgary Depression Scale for Schizophrenia 
(CDSS), Positive and Negative Syndrome Scale (PANSS), while functioning was measured using 
the Global Assessment of Functioning split version function (GAF-F) and symptom scale (GAF-S).  
The clinical assessment team consisted of clinical psychologists and psychiatrists, who were all 
trained until satisfactory inter-rater reliability was obtained
23,24
. Psychotic symptoms were 
examined in the SCZ group using the PANSS 5-factorial model
25
, while depressive and 
hypomanic/manic symptoms were investigated in the BD group using YMRS, IDS and CDSS. 
7 
 
Neurocognitive Assessment: Psychologists trained in standardized neuropsychological testing 
performed neurocognitive assessment. Working memory was assessed with the Digit Span Test—
backward (Wechsler Adult Intelligence Scale [WAIS] -III), letter number sequencing (WAIS-III) 
and the Working Memory—Mental Arithmetic (WM-MA) Test—commissions
26
. For details see 
27
. 
Cytokine Assessment: We used enzyme-linked immunosorbent assay to quantify protein levels due 
to its high specificity and sensitivity
28
, and measured plasma levels of TNF using a high sensitivity 
enzyme immunoassay (EIA) from Cloud Corp (Housten, TX) while  sTNFR1, sTNFR2 and 
sADAM17  was analyzed using EIAs from R&D systems (Minneapolis, MN). Intra- and inter-assay 
coefficients of variance for proteins were less than 10%. The ratio between TNF and sTNFRs may 
provide an estimate of the molar balance in serum between TNF molecules and sTNFRs. In 
molecular terms, this ratio was defined as TNF (pmol/L)/(sTNFR1 + sTNFR2)(pmol/L) X 100, 
assuming a molecular mass of (17 x 3) kD and 30 kD for TNF (trimer) and both types of sTNFRs, 
respectively.  
RNA isolation and RT-PCR: Total RNA was isolated from whole blood using the Tempus 12-Port 
Isolation kit (Applied Biosystems; Ambion, Austin, TX, USA) and quantified using the ND-1000 
spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The tubes were stored at (-
)80
o
C. Reverse transcription was performed using a High Capacity cDNA Archive Kit (Applied 
Biosystems, Foster City, CA) with ~0.5 μg total RNA in 96-well PCR plates (Applied Biosystems). 
Each plate contained 80 samples that were randomly distributed to atone for the differences in 
reverse transcription or subsequent real-time PCR efficiency. 
Quantification of mRNA is described in detail in the Supplementary Text. We used Primer Express 
software version 3.0 (Applied Biosystems) to design sequence specific mRNA (primer spanning 
exon-exon junction) oligonucleotide primers for the full-length TNF, TNFR1, TNFR2 and ADAM17 





Post-Mortem Brain sample collection:  
Details of tissue acquisition, handling, processing, dissection, clinical characterization, diagnoses, 
neuropathological examinations, RNA extraction and quality control measures were described 
previously
29
. Toxicological analysis was performed on every case. For control cases, subjects with 
evidence of macro- or microscopic neuropathology, drug use, alcohol abuse or psychiatric illness 
were excluded.  
 
Post-Mortem Brain RNA extraction and sequencing 
Details of post-mortem DLPFC RNA extraction and sequencing, and RNA Seq data processing 
were previously described
30
. Total RNA was extracted from ~100 mg of post-mortem tissue 
homogenates of DLPFC gray matter approximating BA9/46 in postnatal samples using the RNeasy 
kit (Qiagen) according to the manufacturer's protocol. The poly(A)-containing RNA molecules 
were purified from 1 μg DNase-treated total RNA and, following purification, fragmented into 
small pieces using divalent cations under elevated temperature. Reverse transcriptase and random 
primers were used to copy the cleaved RNA fragments into first-strand cDNA, and the second-
strand cDNA was synthesized using DNA polymerase I and RNase H. We performed the 
sequencing library construction using the TruSeq RNA Sample Preparation v2 kit by Illumina (See 
Supplementary Text for details).  
 
Post-Mortem Analyses: RNA sequencing data processing 
The Illumina Real Time Analysis (RTA) module performed image analysis, base calling and ran the 
BCL converter (CASAVA v1.8.2), generating FASTQ files containing the sequencing reads. These 
reads were aligned to the human genome (UCSC hg19 build) using the spliced-read mapper TopHat 
(v2.0.4) using the reference transcriptome to initially guide alignment, on the basis of known 
transcripts of Ensemble Build GRCh37.67 (the “-G” argument in the software). A normalized reads 
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per kilobase million (RPKM) metric were calculated for each gene by dividing the number of reads 
mapping to the gene divided by the length of the gene (in kilobases). 
 
Statistical analysis 
Plasma and leukocyte cohort analyses: Statistical analyses were performed using the SPSS software 
package for Windows, version 22.0. Data normality was assessed using the Kolmogorov-Smirnov 
and Shapiro-Wilk tests. Differences in demographic data between groups were investigated using 
the chi-square test for categorical variables, the Kruskal-Wallis test for continuous variables, and 
Tukey and the Mann-Whitney U test for post hoc analyses.  We used T-tests for normally 
distributed variables, and non-parametric tests (Mann Whitney U test) for skewed distributions to 
investigate differences between groups. Correlations were examined by using Spearman’s Rank 
correlation. 
Potential confounders (age, sex, smoking status, body mass index [BMI], time for blood sampling 
and race) were investigated using non-parametric tests (Spearman’s rank correlation and Mann-
Whitney U test), and confounders with a p-value lower than 0.2 were controlled for in linear 
regression models. Results are given as standardized beta or T-test from the regression analyses. 
We calculated an aggregate working memory score from the three working memory tasks and 
controlled for age, gender, diagnosis and investigated interaction effects of diagnosis in general 
linear models. 
We corrected for multiple testing according to Bonferroni, and alpha was set at p < 0.007 for the 
main analyses in the circulation (correcting for 7 tests: TNF, sTNFR2, sADAM17, TNF mRNA, 





Post-mortem analyses: Differential expression analysis was performed using LIMMA R package
31
. 
For SCZ versus HC samples, gene RPKM was regressed against a binary diagnosis variable, 
covarying for 8 principal components and covariates of age, sex, and mitochondrial mapping rate, 
with the number of components determined for the expression matrix of a set of 562 immune genes 
(Birnbaum et al, under review) using the sva R package (surrogate variable analysis)
32
.  The 
optimum number of components was determined based on an iterative algorithm to remove the 
impact of mRNA quality on differences in expression between patients and controls that is not 
accounted for by controlling only for RIN and demographic variables. For BD versus HC samples, 
gene RPKM was regressed against a binary diagnosis variable, covarying in this case for 10 
principal components and age, sex, and mitochondrial mapping rate. A multiple testing correction, 
FDR, was employed to correct for all immune genes in the matrix of immune genes from which the 




Demographics and clinical characteristics 
The socio-demographic and clinical characteristics of the participants are presented in Tables 1 and 
2.  
Plasma levels of TNF related molecules  
The plasma levels of TNF related molecules in absolute values are summarized in Table 3. The 
patient group as a whole as well as the SCZ and the BD groups separately had significantly higher 
levels of TNF, sTNFR1and sTNFR2 as well as the TNF/sTNFRs ratio as an estimate of TNF 
activity compared to HC, also in adjusted analysis (i.e. confounders). In contrast, patients had lower 
levels of sADAM17 compared to HC in adjusted analysis.  This pattern, however, was restricted to 
the SCZ group, with no significant difference between the BD and HC group (Table 4). 
TNF, TNFR1, TNFR2 and ADAM17 mRNA expression in whole blood  
The mRNA expression levels of TNF related molecules in whole blood are summarized in Table 3. 
The patient group as a whole as well as the SCZ and BD groups independently had lower levels of 
TNF mRNA compared to HC, with no difference between SCZ and BD (Table 4). In contrast, there 
were no differences in TNFR1 mRNA and TNFR2 mRNA between patients and controls (Table 4). 
However, patients had significantly higher levels of ADAM17 mRNA compared to HC after 
controlling for confounding factors. This effect was clearly driven by the BD group (Table 4). 
TNF proteins and working memory 
Performance on working memory tasks is presented in Supplementary Table 5. We found 
significant associations between working memory and TNF-ratio and TNF that were significantly 
stronger in the SCZ group compared to CTR and BD (data not shown), and remained significant 
after correcting for multiple testing and controlling for age, sex, PANSS score and antipsychotics in 
12 
 
the SCZ group (TNF-ratio: F (5,120)=2.90, adjusted R
2
=0.07,  β=-0.23, p=0.008) (TNF: F 
(5,122)=3.35, R
2
=0.09, β=-0.26, p=0.003) (Supplementary Table 6). 
 
TNF, TNFR1, TNFR2 and ADAM17 mRNA expression in cortex  
As shown in Supplementary Figure 1 and Table 4, there were no differences in mRNA levels of 
TNF (FDR= 0.99), TNFR1 (FDR=0.84), TNFR2 (FDR=0.92) or ADAM17 (FDR=0.95) between 
SCZ and HC. Similarly, no differences in mRNA levels of TNF (FDR=0.76), TNFR1 (FDR=0.77), 
TNFR2 (FDR=0.99) or ADAM17 FDR=0.39) were detected between BD and HC. 
Correlation between TNF-related molecules in plasma (protein) and whole blood (mRNA) 
The associations between protein and mRNA of the TNF related molecules in plasma and whole 
blood, respectively, are presented in Supplementary Table 1. We found moderate but highly 
significant associations between TNFR1, TNFR2 and ADAM17 mRNA, and significant weak 
associations between sTNFR1 and sTNFR2 in both the HC group and the patient group after 
controlling for confounders. Importantly, however, except for a weak correlation between mRNA 
and protein levels of TNFR1 in the patient group as a whole and those with SCZ, there was no 
significant correlation between protein and mRNA levels of the different TNF related molecules 
(Supplementary Table 1).   
Role of medication 
Patients using lithium (n=19) had higher levels of ADAM17 mRNA and sTNFR1 levels compared 
to non-medicated (n=85) patients in the BD group. Serum levels of lithium were associated with 
higher TNF levels and increased TNF/sTNFRs ratio (Supplementary Table 2), however, these 
results do not remain significant after correction for multiple testing. We found no other significant 
associations between medication groups (antipsychotics, mood stabilizers and antidepressants), 
medication dosage and cytokines/mRNA. 
13 
 
Clinical characteristics and TNF pathway expression and cytokines 
We found weak correlations with small effect sizes between clinical symptoms (i.e., PANSS, GAF 
and CDSS) and TNF pathway related gene expression and corresponding proteins. These results, 
however, do not survive correction for multiple testing (Supplementary Table 3-4).  
PANSS, GAF and duration of illness in the SCZ group: We found weak negative associations after 
controlling for confounders between TNF mRNA and PANSS excited symptoms, TNFR1 mRNA 
and PANSS negative symptoms, TNF and GAF-symptom scale, sTNFR1 and GAF-symptoms scale, 
and TNF mRNA and duration of illness. Thus, it seems that decreased TNF and TNFR1 mRNA 
expression was associated with increased disease symptom severity, while increased circulating 
TNF and sTNFR1 was associated with increased symptom severity. 
CDSS, IDS, YMRS, GAF and duration of illness in the BD group: We found a weak positive 
association after controlling for confounders between TNF mRNA and duration of illness in the BD 
group (the opposite of what we found in the SCZ group). Of the clinical symptoms only CDSS 
showed associations with cytokines and mRNA; increasing sTNFR2 levels and TNFR2 mRNA 
expression were associated with decreased depressive symptoms, while increased TNF mRNA 





We found that patients with SCZ and BD had slightly increased plasma levels of TNF-related 
molecules with significantly increased TNF/sTNFRs ratio, which has been shown to be a surrogate 
marker of TNF bioactivity
12
, compared to HC suggesting a subtle but potentially biologically 
relevant pro-inflammatory imbalance in the TNF system in these disorders. However, while TNF 
levels were elevated in plasma, TNF mRNA was decreased in whole blood suggesting other cellular 
sources of TNF than circulating leukocytes (Figure 1). The increased ADAM17 mRNA expression 
detected in BD compared to SCZ in peripheral blood could potentially contribute to increase 
shedding of membrane-bound TNF in BD, suggesting a differential role for ADAM17 in BD 
compared to SCZ. We have previously reported that elevated plasma levels of sTNFR1 were 
associated with lower scores on several cognitive tests
20,33
. Here, we found that a shift toward a pro-
inflammatory imbalance in the TNF pathway was weakly but significantly associated with lower 
working memory scores potentially suggesting a link between the DLPFC and the TNF pathway, 
however, we observed no significant alterations in TNF-system mRNA expression in the DLPFC of 
patients compared to HC.  
The increased levels of TNF, sTNFR1 and sTNFR2 in SCZ and BD patients per se may not 
necessarily reflect a pro-inflammatory shift in the TNF-pathway considering that soluble TNF 
receptors partake in regulating TNF activity by acting as decoy receptors and competing with 
membrane-bound receptors for TNF
34
. However, our results suggest that while both plasma levels 
of TNF and its soluble receptors are elevated in SCZ and BD, there is also a pro-inflammatory 
imbalance as shown by increased TNF/sTNFRs ratio
12
. In spite of this pro-inflammatory imbalance 
in plasma, and in contrast to previous more small-scaled studies
13,14
, TNF mRNA was down-
regulated in circulating leukocytes from both BD and SCZ patients implying other cellular sources 
for the elevated plasma levels in these disorders, such as endothelial cells and tissue macrophages 
(Figure 1). Based on the distinct upregulation of ADAM17 mRNA in leukocytes in BD and the role 
of ADAM17 in the release of TNF and its receptor from their membrane to their soluble form, it is, 
15 
 
however, possible that increased shedding of these molecules could contribute to their increased 
plasma levels in BD patients, potentially representing a distinct pattern of this disorder.  
We predicted that these results in peripheral blood would be recapitulated in the DLPFC.  
Using a conservative method to control for mRNA quality in brain tissue, which is a major 
confounder of prior studies that control only for RIN and demographics, we find no evidence of the 
changes in peripheral blood in prefrontal cortical samples from either patients with SCZ or BD.  It 
is important to recognize that our mRNA quality adjustment is rigorous and conservative and 
though potentially sensitive to type II error, is robust in controlling for Type I error.  The lack of 
changes in the expression of TNF related signaling molecules in the DLPFC per se cannot rule out 
altered TNF-pathway activity in other regions of the brain or the possibility that inflammatory 
molecules in peripheral blood have CNS effects without changing intrinsic gene expression. Indeed, 
cytokines in peripheral blood are able to cross the blood brain barrier
35





 and neural activity and viability
36
. Our findings raise questions, 
however, about whether TNF signaling in peripheral blood is a marker of a primary 
pathophysiological process or secondary to other disease mechanisms. Notably, enhanced TNF 
activity is associated with several co-morbid metabolic conditions such as type 2 diabetes and 
cardiovascular disease
37,38
. However, it is important to underscore that the cortex analyses were 
performed on whole cortex samples and not on isolated cells, and an up- or down-regulation for 
example in microglia may be masked by expression in other cells.  Correlations between clinical 
features, treatment and TNF measures in peripheral blood were largely uninformative showing a 
rather complex pattern. However, increasing depressive symptoms were associated with a moderate 
increase in TNF mRNA, and lower levels of sTNFR2, TNFR1 and TNFR2 mRNA suggesting a pro-
inflammatory imbalance in circulating immune cells of these patients, further supporting a potential 
link between TNF activity and depression as described by others
39
. We found no significant 
difference in plasma/whole blood cytokine/mRNA levels between patients using antipsychotics in 
monotherapy and non-medicated patients, and no significant correlation between defined daily 
16 
 
dosage of antipsychotics and cytokine/mRNA levels. This is in contrast to previous smaller studies 
that have found that antipsychotics may influence the expression of TNF
40
. However, plasma levels 
of TNF and TNF/sTNFRs ratio increased with higher lithium serum concentrations, and patients 
using lithium had higher sTNFR1 and ADAM17 mRNA levels compared to non-medicated bipolar 
patients, suggesting that lithium may promote activation of the TNF system.  
There are some limitations to our study. Firstly, there is a difference in the time of blood 
sampling for our HC group compared to the patient group, but this was controlled for in the analysis 
of cytokine and mRNA levels. Secondly, current RNA sequencing quantification and mapping 
methods may lead to potential underestimation of mRNA levels. Further, although previous studies 
have measured TNF related proteins in postmortem brain
41
, we were unable to obtain reliable data 
on postmortem TNF pathway proteins. Finally, our data on the association of TNF molecules and 
clinical symptoms should be interpreted with caution as no consistent patterns were observed.    
This is by far the largest study that investigates the TNF system in patients with severe 
mental disorders, including both plasma levels as well as mRNA expression in whole blood and in 
brain. Our data suggest a complex regulation of TNF related molecules in peripheral blood of BD 
and SCZ patients with increased TNF/sTNFRs ratio in plasma, reflecting enhanced TNF activity as 
a major finding. The highly significant difference in ADAM17 mRNA expression between SCZ and 
BD may also implicate other ADAM17 substrates and respective systems in the pathology of BD, 
and requires further elucidation. Our findings also suggest that circulating leukocytes are not a 
major source of soluble TNF levels in plasma. The lack of findings in the DLPFC leaves unresolved 
the issue of how peripheral blood alterations relate to the TNF system in the brain. Further studies 
are needed to investigate other cortical regions of the brain and the impact of our findings on the 
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Table 1. Demographic and clinical characteristics of participants. 
Parameters 
Plasma (cytokine/protein) cohort Leukocyte (mRNA) cohort 
SCZ 
(N = 569) 
BD 
(N = 247) 
HC 




(N = 224) 
BD 
(N = 143) 
HC 
(N = 184) 
Post Hoc  
Analysis 
Male sex, N (%) 340 (59.8) 103 (41.7) 330 (52.9) SCZ > HC > BD 127 (56.7) 51 (35.7) 108 (58.7) HC, SCZ > BD 
Ethnicity (Caucasian) 453 (79.6) 222 (89.9) 611 (97.9) HC > BD > SCZ 178 (79.5) 132 (92.3) 184 (100) HC > BD > SCZ 
Tobacco (users)
a
 300 (54.8) 131 (54.6) 55 (19.9) SCZ, BD > HC 118 (57.3) 66 (56.4) 24 (20.5) SCZ, BD > HC 
Medication:         
   Antipsychotics 488 (85.8) 128 (51.8) - SCZ > BD 189 (84.4) 76 (53.1) - SCZ > BD 
   Lithium 9 (1.6) 50 (20.3) - BD > SCZ 4 (1.8) 20 (14.0) - BD > SCZ 
   Antidepressants 179 (31.5) 95 (38.8) - BD > SCZ 36 (16.1) 65 (46.1) - BD > SCZ 
   Mood stabilizers 76 (13.4) 98 (40.2) - BD > SCZ 61 (27.2) 54 (38.0) - BD > SCZ 
Age (years) 27 (15) 32 (18) 32 (13) BD, HC > SCZ 29 (15) 31 (16) 31.5 (13) NS 
Body Mass Index
b
 25.7 (7.1) 25.4 (5.6) 24.4 (4.4) BD, SCZ > HC 25.9 (7.4) 25.4 (5) 24.5 (4.29) SCZ > HC 
Duration of Illness (years) 4 (8) 9 (13) - BD > SCZ 4.5 (7.8) 8 (10.5) - BD > SCZ 
Time of blood sampling
c
 09:45 (1:10) 09:27 (0:55) 12:42 (6:50) HC > SCZ > BD 09:50 (1:00) 09:30 (1:00) 11:10 (6:50) HC > SCZ > BD 
PANSS total score 62 (22) 45 (13) - SCZ > BD 63 (22) 44 (13) - SCZ > BD 
YMRS total score 4.0 (9) 2 (6) - SCZ > BD 5 (9) 1 (4) - SCZ > BD 
IDS total score 17 (20) 15 (18) - NS 17 (21) 14 (19) - NS 
CDSS total score 5 (7) 3 (6) - SCZ > BD 5 (8) 2.5 (7) - SCZ > BD 
GAF-S 40 (13) 55 (16) - BD > SCZ 39 (13) 57 (15) - BD > SCZ 
GAF-F 41 (15) 50 (20) - BD > SCZ 40 (13) 51 (17) - BD > SCZ 
Missing: 
a 
N = 369, 
b
 N = 319, 
c
 N = 422 in the plasma cohort 
Abbreviations: HC = Healthy Controls; SCZ = Schizophrenia Spectrum; BD = Bipolar Disorder; NS = Non-Significant; PANSS=Positive and Negative Syndrome 
Scale; YMRS=Young Mania Rating Scale; IDS=Inventory of Depressive Symptoms; CDSS= Calgary Depression Scale for Schizophrenia; GAF-F = Global 
Assessment of Functioning - Function Scale; GAF-S = Global Assessment of Functioning - Symptom Scale. 
Categorical data are given as percent in brackets, while continuous data are given as median with interquartile range. Post hoc analysis is performed using Pearson 








(N = 80) 
BD 
(N = 44) 
HC 
(N = 88) 
Male sex, N (%) 54 (73.8) 23 (52.3) 69 (78.4) 
Ethnicity (Caucasian) 80 (100) 44 (100) 88 (100) 
Mean age (SE) 46.5 (1.8) 46.8 (2.1) 44.7 (1.7) 
Mean RIN (SE) 8.2 (0.06) 8.3 (0.08) 8.4 (0.05) 
Abbreviations: SCZ = schizophrenia; BD = Bipolar Disorder; HC= Healthy Controls, SE = Standard Error, 





Table 3. Unadjusted data: Protein levels in plasma, relative mRNA expression in peripheral blood, and mRNA 
expression in the dorsolateral prefrontal cortex. 
Parameters 
Schizophrenia Bipolar Disorder Healthy Controls 
N M (IQR) N M (IQR) N M (IQR) 
Plasma cytokine/protein       
TNF (pg/mL) 352 1.20 (1.28) 168 1.16 (1.04) 358 1.09 (1.03) 
sTNFR1 (ng/mL) 569 1.76 (0.74) 247 1.67 (0.52) 624 1.60 (0.77) 
sTNFR2 (ng/mL) 553 4.76 (1.43) 239 4.60 (1.47) 591 4.51 (1.44) 
ADAM17 (pg/mL) 548 189 (282) 240 227 (358) 594 214 (341) 
Leukocyte mRNA       
TNF mRNA 224 0.89 (0.44) 142 0.92 (0.41) 184 1.00 (0.58) 
TNFR1 mRNA 224 1.02 (0.32) 143 1.08 (0.46) 184 1.00 (0.31) 
TNFR2 mRNA 224 0.98 (0.36) 143 1.00 (0.46) 184 1.00 (0.43) 
ADAM17 mRNA 224 1.02 (0.29) 142 1.24 (0.46) 184 1.00 (0.38) 
DLPFC  mRNA       
TNF mRNA 80 0.03 (0.05) 44 0.03 (0.06) 86 0.02 (0.05) 
TNFR1 mRNA 80 3.87 (3.10) 44 3.19 (2.43) 86 2.35 (0.77) 
TNFR2 mRNA 80 1.74 (1.20) 44 1.37 (0.63) 86 1.44 (0.64) 
ADAM17 mRNA 80 3.25 (0.95) 44 2.83 (0.91) 86 3.40 (0.94) 
Abbreviations: TNF=tumor necrosis factor; sTNFR1 =soluble TNF receptor 1; sTNFR2=soluble TNF 
receptor 2; ADAM17=A Disintegrin And Metalloprotease-17 protein; DLPFC= dorsolateral prefrontal 
cortex;IQR=interquartile range; M = median, ng = nanogram; pg = pictogram.  





Table 4. Differences in cytokine and mRNA levels between patients and controls after controlling 
for confounders. 
 Plasma cohort 
(soluble cytokine) 




n β t n β t t FC FDR 
Patients vs. HC 
TNFR1 1003 .14 4.47*** 472 .05 1.11    
TNFR2 1000 .10 2.94** 315 .11 1.56    
TNF 459 .17 3.48** 564 -.16 -3.91***    
ADAM17 1415 - -2.08* 428 .16 3.15**    
TNF/sTNFRs 
ratio 
455 .20 4.07***       
          
SCZ vs. HC          
TNFR1 748  .15  3.82***  309 .01  .15 .79 1.02 .84 
TNFR2 828 .09 2.56* 239 .14  1.71 -.40 .99 .92 
TNF 319 .16 2.38* 323 -.18 -3.02** -.04 1.00 .99 
ADAM17 744 - -2.93** 323 .02  .28 -.33 .99 .95 
TNF/sTNFRs 
ratio 
317 .16 2.48*       
BD vs. HC          
TNFR1 479   .17  3.50**  264 .05  .81 -.61 .99 .77 
TNFR2 516  .15 3.42** 234 .04  .57 -.01 1.0 .99 
TNF 189  .19 2.61** 326 - -2.56* .64 1.01 .76 
ADAM17 315 -.03 -.48 222 .40  5.92*** 1.62 1.05 .39 
TNF/sTNFRs 
ratio 
195   .22 2.72**       
          
BD vs. SCZ          
TNFR1 478 -.07 -1.46 367 .06 1.12    
TNFR2 696 -.06 -1.54 367 -.07 -1.25    
TNF 347 -.07 -1.28 366 .01 .11    
ADAM17 510  .06  1.42 366 .39 8.03***    
TNF/sTNFRs 
ratio 
344 -.02 -.39       
*p < 0.05   **p < 0.01   ***p < 0.001 
Abbreviations: SCZ=schizophrenia; BD=bipolar disorder; HC=healthy controls; TNF=tumor necrosis 
factor; sTNFR1 =soluble TNF receptor 1; sTNFR2=soluble TNF receptor 2; ADAM17=A Disintegrin And 
Metalloprotease-17 protein; TNF/sTNFRs ratio = TNF/(sTNFR1 + sTNFR2) 
The brain cohort: n(HC) = 86, n(SCZ)=79, n(BD) = 44. 





Figure 1.  Elevated soluble plasma cytokine levels in SCZ and BD may be a result of increased 
shedding from their membrane bound form in BD, but blood leukocytes seem an unlikely source as 
TNF mRNA is downregulated in both disorders. There are no strong indications of alterations in 
TNF related signaling molecules in prefrontal cortex, however, soluble plasma cytokines can pass 
through the blood brain barrier, and differential expression of these molecules may occur in other 
regions of the brain. The increase in plasma cytokines may also be a result of heightened immune 




Quantification of whole blood mRNA 
Quantification of mRNA was performed with the q polymerase chain reaction Master Mix for 
SYBR Green I (Applied Biosystems) in 10 μL duplicate reactions in 384 well plates on an ABI 
Prism 7900 (Applied Biosystems) using the 2(-Delta Delta C[T]) method with the average of four 
pools of cDNA. These were included on each plate in the RT-PCR and followed the samples in the 
real time PCR, as reference. The CV was under 10 % for the average of these calibrators between 
all the plates analyzed.   
 
Sequencing library construction  
The sequencing library construction was performed using the TruSeq RNA Sample Preparation v2 
kit by Illumina. Briefly, cDNA fragments undergo an end repair process using T4 DNA polymerase, 
T4 polynucleotide kinase and Klenow DNA polymerase with the addition of a single adenosine 
using a Klenow polymerase lacking 3′ to 5′ exonuclease activity, and then ligated to the Illumina 
paired-end (PE) adapters using T4 DNA ligase. An index/barcode was inserted into Illumina 
adapters, allowing samples to be multiplexed in one lane of a flow cell. These products were then 
purified and enriched with PCR to create the final cDNA library for high throughput DNA 
sequencing using an Illumina HiSeq 2000.
 
Supplementary Table 1. Associations between protein and mRNA in the blood after controlling for 
confounders. 








in HC        
TNF .10 -.02 .02 -.01 -.03 -.04 -.12 
sTNFR1  .20** .08 -.21 .03 -.02 -.06 
sTNFR2   -.01 .00 -.03 -.12 -.06 
sADAM17     -.02 .11 .11 -.01 
TNF mRNA     -.13 -.03 -.06 
TNFR1 mRNA      .48*** .68*** 
TNFR2 mRNA       .44*** 
in SCZ+BD        
TNF .08 .15* .13* -.05 -.01 .06 .02 
sTNFR1  .33*** .01 -.07 .15* -.06 -.01 
sTNFR2   -.02 -.18** .08 -.02 -.05 
sADAM17     -.08 .00 -.04 .04 
TNF mRNA     -.08 -.12* .16** 
TNFR1 mRNA      .48*** .44*** 
TNFR2 mRNA       .39*** 
in SCZ        
TNF -.01 16* .12 -.06 -.05 -.05 -.01 
sTNFR1  .41*** .01 -.04 .20** .10 -.02 
sTNFR2   .04 -.04 .09 -.02 .05 
sADAM17    -.05 .00 -.03 -.03 
TNF mRNA     .00 -.16* .12 
TNFR1 mRNA      .44*** .51*** 
TNFR2 mRNA       .45*** 
in BD        
TNF .16* .09 .19* -.01 -.04 .11 .02 
sTNFR1  .19* .07 -.22 .15 .15 .10 
sTNFR2   -.06 -.30** .15 .02 -.07 
sADAM17     -.17 -.04 -.06 -.08 
TNF mRNA     -.27** -.08 .26** 
TNFR1 mRNA      .50*** .34** 
TNFR2 mRNA       .48*** 
*p < 0.05   **p < 0.01   ***p < 0.001 
Abbreviations: SCZ = Schizophrenia; BD = Bipolar Disroder; HC = Healthy Controls; TNF=tumor 
necrosis factor; sTNFR1 =soluble TNF receptor 1; sTNFR2=soluble TNF receptor 2; TNF/sTNFRs 
ratio = TNF/(sTNFR1 + sTNFR2); ADAM17=A Disintegrin And Metalloprotease-17 protein. 
Results are given as standardized beta from linear regression analyses.  
Supplementary Table 2. Associations between daily defined dose of medication and protein/mRNA levels, and group effect of medication vs. non-medicated patients 
after controlling for confounders and diagnosis. 
 Serum cohort mRNA cohort 









DDD associations:          
   Antipsychotics .07 -.07 -.02 -.04  .04  .09  .21 -.04  .11 
   Lithium .42** -.14 -.01  .39*  .01 -.40  .15  .15  .42 
   Mood stabilizers .02  .08  .11 -.03  .06 -.01 -.08  .04 -.03 
   Antidepressants .07 -.01  .14  .03 -.07 -.04 -.02  .08 -.08 
Group effects:          
   Antipsychotics -1.11 1.79  .29 -.08   -.15 -1.32 -.82    .02 -1.19 
   Lithium    .24 2.34*  .52  .41   -.33   -.37 -.24   -.29  2.24* 
   Mood stabilizers   -.10 1.50  .75 -.23 -1.17 -1.24 -.48   -.75 -1.09 
   Antidepressants    .08 1.69  .45  .28 -1.00 -1.28 -.25 -1.24 -1.52 
*p < 0.05   **p < 0.01 
Abbreviations: DDD = daily defined dose; TNF=tumor necrosis factor; TNF=soluble TNF; sTNFR1 =soluble TNF receptor 1; sTNFR2=soluble TNF 
receptor 2; TNF/sTNFRs ratio = TNF/(sTNFR1 + sTNFR2); ADAM17=A Disintegrin And Metalloprotease-17 protein. 
Results are given as standardized beta from linear regression analyses for associations and as T-values from linear regression analyses for medication 
effects. 
Only antipsychotics were investigated as monotherapy due to small sample sizes in the other medication groups. We used serum concentration of 
lithium instead of DDD, and differences in ADAM17 mRNA levels were examined in the bipolar disorder group. 
 




Supplementary Table 3. Associations between protein/ mRNA and clinical characteristics in 
schizophrenia. 
 DOI Pos. Neg. Disorg. Excited Depr. GAF-S GAF-F 
TNF .05 .03 .04 .10 .05 .09 -.14* -.12 
sTNFR1 .05 .05 .08 .04 .03 -.03 -.14** -.08 
sTNFR2 .01 .06 .08 .02 .02 -.02 -.08 -.08 
ADAM17 .03 .01 .02 .00 -.06 -.04 -.01 .01 
TNF/sTNFRs ratio .10 .02 -.03 .07 .05 .11 -.11 -.10 
TNF mRNA -.14* -.07 .02 -.10 -.17* .02 .13 .13 
TNFR1 mRNA -.06 -.05 -.14* .06 -.07 -.07 .00 -.08 
TNFR2 mRNA -.07 -.08 -.06 .06 .07 -.09 .08 .00 
ADAM17 mRNA -.08 -.09 -.12 -.04 -.12 -.06 .07 .00 
*p< 0.1; **p<0.01 
Abbreviations: DOI=Duration of illness; PANSS=Positive and Negative Syndrome Scale, 5-
factorial model
1
; Pos.=PANSS Positive symptoms; Neg.=PANSS Negative symptoms; 
Disorg.=PANSS  disorganized symptoms; Depr.=PANSS depressive symptoms; GAF-F=Global 
Assessment of Functioning - Function Scale; GAF-S=Global Assessment of Functioning - 
Symptom Scale; TNF=tumor necrosis factor; sTNFR1 =soluble TNF receptor 1; sTNFR2=soluble 
TNF receptor 2; ADAM17=A Disintegrin And Metalloprotease-17 protein; TNF/sTNFRs ratio = 
TNF/(sTNFR1 + sTNFR2).  
Associations are given as standardized beta after controlling for confounders in linear regression 
analyses. ADAM17 mRNA was not associated with the selected confounders and is therefore 
investigated using Spearman’s Rank correlation. 
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Supplementary Table 4. Associations between protein/mRNA and clinical characteristics in bipolar 
disorder. 
 DOI CDSS IDS YMRS GAF-S GAF-F 
TNF .03 -.08 -.04 .07 .01 .07 
sTNFR1 -.02 .08 .09 .07 .02 .06 
sTNFR2 -.09 -.22** -.06 -.08 .09 .05 
ADAM17 -.03 -.04 .01 .10 -.10 -.12 
TNF/sTNFRs ratio .05 .04 .01 .12 -.08 -.06 
TNF mRNA .13 .35** .14 .01 -.06 .01 
TNFR1 mRNA -.04 -.18 .00 .03 .03 .02 
TNFR2 mRNA -.12 -.27* -.07 .04 .06 .01 
ADAM17 mRNA .05 -.17 -.06 .03 .03 .07 
*p< 0.1; **p<0.01 
Abbreviations: DOI=Duration of illness; YMRS=Young Mania Rating Scale; IDS=Inventory of 
Depressive Symptoms; CDSS=Calgary Depression Scale for Schizophrenia; GAF-F=Global 
Assessment of Functioning - Function Scale; GAF-S=Global Assessment of Functioning - 
Symptom Scale; TNF=tumor necrosis factor; sTNFR1 =soluble TNF receptor 1; sTNFR2=soluble 
TNF receptor 2; ADAM17=A Disintegrin And Metalloprotease-17 protein; TNF/sTNFRs ratio = 
TNF/(sTNFR1 + sTNFR2). 
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Supplementary Table 5. Performance on working memory tasks. 
Parameters 
Schizophrenia Bipolar Disorder Healthy Controls 
ANOVA/Kruskal-Wallis 
and Post Hoc analyses 
N M (SD) N M (SD) N M (SD) 
Digit Span Test—backward 
(WAIS-III) 
128 4.26 (1.06) 88 4.69 (1.30) 28 4.96 (0.92) CTR,BD > SCZ 
Letter Number Sequencing 
(WAIS-III)   
128 9.54 (2.80) 88 10.07 (2.16) 28 11.54 (2.55) CTR > BD,SCZ 
WM-MA 128 2.68 (1.09) 88 3.00 (0.96) 28 3.46 (0.72) CTR > BD,SCZ 
Working Memory 
Aggregate Score 
128 0.74 (0.77) 88 1.02 (0.71) 28 1.43 (0.63) CTR > BD > SCZ 
Abbreviations: WAIS-III= Wechsler Adult Intelligence Scale-III; WM-MA= Working Memory—Mental Arithmetic. M=mean, SD=standard 
deviation. Digit span test-backward and letter number sequencing test are given as raw score. WM-MA is given as d-prime. Working memory 
aggregate score is calculated from z-scores of the 3 tasks. Differences between groups were investigated using ANOVA for working memory 
aggregate score, and Kruskal-Wallis test for the remaining 3 tests. Post Hoc analyses were performed using Tukey and Mann-Whitney test 
respectively. 
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Supplementary table 6. Stepwise linear regression analyses investigating working memory as dependent variable in the schizophrenia group. 
 TNF-ratio (β) age (β) sex (β) PANSS total (β) Antipsychotics (β) adj. R
2
 F (df) 
model 1 -.25**     .05 F(1,124) = 8.05*** 
model 2 -.26** -.07 -.10   .05 F (3,122) = 3.40* 
model 3 -.24** -.10 -.10 -.16  .07 F (4,121) = 3.48* 
model 4 -.23** -.10 -.10 -.17 -.07 .07 F (5,120) = 2.90* 
        
 TNF (β) age (β) sex (β) PANSS total (β) Antipsychotics (β) adj. R
2
 F (df) 
model 1 -.28**     .07 F (1,126) = 10.61** 
model 2 -.28** -.06 -.10   .07 F (3,124) = 4.27** 
model 3 -.27** -.09 -.11 -.15  .09 F (4,123) = 4.02** 
model 4 -.26** -.09 -.10 -.16 -.07 .09 F (5,122) = 3.35** 
*p<0.05 **p<0.01 ***p<0.001 
Abbreviations: TNF=Tumor Necrosis Factor; PANSS=Positive and Negative Syndrome Scale. 
Results are given as standardized β from linear regression analysis. 
 
Hoseth EZ  8 
 
Supplementary Figure 1. Results from post-mortem prefrontal cortex RNA sequencing. 
SCZ vs HC 
 
 




No significant difference in TNFR1, TNFR2 and ADAM17 and TNF mRNA expression between 
patients and controls in the post-mortem sample. SCZ (n=80), BD (n=44) and HC (n=86). Y-axis is 
Log2RPKM+1 adjusted for principal components, age sex, and mitochondrial mapping rate. FDR is 
multiple testing correction for expression matrix of n=562 immune genes (elsewhere reported). 
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